85 related articles for article (PubMed ID: 15921782)
1. Urotensin II in patients with chronic heart failure.
Krüger S; Graf J; Kunz D; Stickel T; Merx MW; Hanrath P; Janssens U
Eur J Heart Fail; 2005 Jun; 7(4):475-8. PubMed ID: 15921782
[TBL] [Abstract][Full Text] [Related]
2. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.
Lapp H; Boerrigter G; Costello-Boerrigter LC; Jaekel K; Scheffold T; Krakau I; Schramm M; Guelker H; Stasch JP
Int J Cardiol; 2004 Mar; 94(1):93-7. PubMed ID: 14996481
[TBL] [Abstract][Full Text] [Related]
4. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers.
Gruson D; Rousseau MF; Ahn SA; van Linden F; Ketelslegers JM
Peptides; 2006 Jun; 27(6):1527-31. PubMed ID: 16364499
[TBL] [Abstract][Full Text] [Related]
5. Plasma urotensin II in heart failure.
Richards AM; Nicholls MG; Lainchbury JG; Fisher S; Yandle TG
Lancet; 2002 Aug; 360(9332):545-6. PubMed ID: 12241661
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of changes of urotensin II in patients with congestive heart failure].
Zhong P; Li ZL; Wu HC; Tang CS; Lu Q
Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):121-3. PubMed ID: 12581957
[TBL] [Abstract][Full Text] [Related]
7. Possible pathogenic link between migraine and urotensin-II.
Bicak U; Karabiber H; Ozerol HI; Aslan M; Ilhan A; Yakinci C
J Child Neurol; 2008 Nov; 23(11):1249-53. PubMed ID: 18984832
[TBL] [Abstract][Full Text] [Related]
8. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure.
Kinugawa T; Kato M; Ogino K; Osaki S; Igawa O; Hisatome I; Shigemasa C
J Card Fail; 2003 Aug; 9(4):318-24. PubMed ID: 13680553
[TBL] [Abstract][Full Text] [Related]
9. Urotensin II: a cardiovascular and renal update.
Zoccali C; Mallamaci F
Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):199-204. PubMed ID: 18277155
[TBL] [Abstract][Full Text] [Related]
10. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.
Russell FD; Meyers D; Galbraith AJ; Bett N; Toth I; Kearns P; Molenaar P
Am J Physiol Heart Circ Physiol; 2003 Oct; 285(4):H1576-81. PubMed ID: 12791592
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive measurement of stroke volume during exercise in heart failure patients.
Agostoni PG; Wasserman K; Perego GB; Guazzi M; Cattadori G; Palermo P; Lauri G; Marenzi G
Clin Sci (Lond); 2000 May; 98(5):545-51. PubMed ID: 10781385
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.
Dschietzig T; Bartsch C; Pregla R; Zurbrügg HR; Armbruster FP; Richter C; Laule M; Romeyke E; Neubert C; Voelter W; Baumann G; Stangl K
Regul Pept; 2002 Dec; 110(1):33-8. PubMed ID: 12468107
[TBL] [Abstract][Full Text] [Related]
13. Renal effects of human urotensin-II in rats with experimental congestive heart failure.
Ovcharenko E; Abassi Z; Rubinstein I; Kaballa A; Hoffman A; Winaver J
Nephrol Dial Transplant; 2006 May; 21(5):1205-11. PubMed ID: 16396970
[TBL] [Abstract][Full Text] [Related]
14. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
Isnard R; Pousset F; Chafirovskaïa O; Carayon A; Hulot JS; Thomas D; Komajda M
Am Heart J; 2003 Oct; 146(4):729-35. PubMed ID: 14564330
[TBL] [Abstract][Full Text] [Related]
15. Exercise stroke volume and heart rate response differ in right and left heart failure.
Groepenhoff H; Westerhof N; Jacobs W; Boonstra A; Postmus PE; Vonk-Noordegraaf A
Eur J Heart Fail; 2010 Jul; 12(7):716-20. PubMed ID: 20413396
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma levels of Urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis?
Balat O; Aksoy F; Kutlar I; Ugur MG; Iyikosker H; Balat A; Anarat R
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):33-8. PubMed ID: 15866083
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
18. [Plasma urotensin II level in patients with chronic congestive heart failure].
Jołda-Mydłowska B; Salomon P; Mazurek W
Pol Arch Med Wewn; 2006 Dec; 116(6):1125-36. PubMed ID: 18634521
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?
Giachini FR; Callera GE; Carneiro FS; Tostes RC; Webb RC
Expert Opin Ther Targets; 2008 Mar; 12(3):327-39. PubMed ID: 18269342
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.
Hirose T; Takahashi K; Mori N; Nakayama T; Kikuya M; Ohkubo T; Kohzuki M; Totsune K; Imai Y
Peptides; 2009 Jun; 30(6):1124-9. PubMed ID: 19463745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
